Pregabalin Capsule
Product Images NDC 71610-894

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-894). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (71610 0894 30)

Label (71610 0894 30)
FDA Label Image

Aphena (Aphena)

Aphena (Aphena)
FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical Structure (Pregabalin 01)
FDA Label Image

Figure 1 (Pregabalin 02)

Figure 1 (Pregabalin 02)
FDA Label Image

Figure 2 (Pregabalin 03)

Figure 2 (Pregabalin 03)
Not available.*
FDA Label Image

Figure 3 (Pregabalin 04)

Figure 3 (Pregabalin 04)
FDA Label Image

Figure 4 (Pregabalin 05)

Figure 4 (Pregabalin 05)
This text provides information on the percentage of patients improved after taking different doses of Pregabalin (200mg three times a day, 100mg three times a day) compared to a placebo. The chart shows the percentage improvement in pain from baseline.*
FDA Label Image

Figure 5 (Pregabalin 06)

Figure 5 (Pregabalin 06)
FDA Label Image

Figure 6 (Pregabalin 07)

Figure 6 (Pregabalin 07)
FDA Label Image

Figure 7 (Pregabalin 08)

Figure 7 (Pregabalin 08)
FDA Label Image

Figure 8 (Pregabalin 09)

Figure 8 (Pregabalin 09)
This is a set of data showing responder rates for different treatments. The responder rates are expressed as percentages for each treatment group. The treatments include Placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rates range from 22.6% to 50.6%.*
FDA Label Image

Figure 9 (Pregabalin 10)

Figure 9 (Pregabalin 10)
The text provides data on the percentage of patients improved for different doses of Preguizsin A0, with 100 patients showing improvement. Additionally, it presents the percentage improvement in pain from baseline for the mentioned doses. This information can be used to evaluate the effectiveness of the medication in relieving pain.*
FDA Label Image

Figure 10 (Pregabalin 11)

Figure 10 (Pregabalin 11)
FDA Label Image

Figure 11 (Pregabalin 12)

Figure 11 (Pregabalin 12)
FDA Label Image

Figure 12 (Pregabalin 13)

Figure 12 (Pregabalin 13)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.